Complement Inhibitors for Treatment of Generalized Myasthenia Gravis

Author(s):

Nicholas J. Silvestri, MD, FAAN,Ali Habib, MD

Key Takeaways

Complement inhibitors target the C5 component of the complement cascade, preventing membrane attack complex formation and reducing neuromuscular junction damage.
Clinical trials show significant efficacy in improving muscle strength and reducing symptoms in gMG patients.
Safety profiles of complement inhibitors are generally favorable, with adverse effects being manageable.
These agents offer a targeted therapeutic approach, addressing the underlying pathophysiology of gMG.

Panelists discuss how complement inhibitors work to treat generalized myasthenia gravis (gMG), evaluating their efficacy and safety profiles based on FDA approvals and clinical experience.

EP: 1.Generalized Myasthenia Gravis Presentation and Diagnosis

EP: 2.Generalized Myasthenia Gravis Classification and Treatment Strategy

EP: 3.Pathophysiology and Standard of Care in Generalized Myasthenia Gravis

EP: 4.Outcome Measures in Generalized Myasthenia Gravis

Now Viewing

EP: 5.Complement Inhibitors for Treatment of Generalized Myasthenia Gravis

EP: 6.Neonatal Fc Receptors in Treatment of Generalized Myasthenia Gravis

EP: 7.Factors Guiding Treatment Selection in Generalized Myasthenia Gravis

EP: 8.Combination Therapy in Generalized Myasthenia Gravis and Treatment of Newly Diagnosed Patients

EP: 9.Nipocalimab and FcRn Inhibitors in Generalized Myasthenia Gravis

EP: 10.Dosing Regimens and Treatment Efficacy of FcRn Inhibitors in Generalized Myasthenia Gravis

EP: 11.Use of Targeted Agents in Generalized Myasthenia Gravis

EP: 12.Management of Generalized Myasthenia Gravis in Pediatric Patients

EP: 13.Unmet Needs in Generalized Myasthenia Gravis

EP: 14.Generalized Myasthenia Gravis Pipeline

EP: 15.New Data from AANEM 2024 in Generalized Myasthenia Gravis

EP: 16.Clinical Pearls for Management of Generalized Myasthenia Gravis

Video content above is prompted by the following:

Complement inhibitor agents have been approved by the FDA for treatment of gMG. Provide an overview of their mechanism of action and your overall impressions of the efficacy and safety of these agents.

Keep your finger on the pulse of neurology—subscribe to NeurologyLive for expert interviews, new data, and breakthrough treatment updates.

Subscribe Now!